Efficacy and Safety of Ketamine to Treat Cancer Pain in Adult Patients: A Systematic Review

氯胺酮 医学 癌症疼痛 麻醉 恶心 止痛药 可视模拟标度 镇静 便秘 随机对照试验 不利影响 呕吐 癌症 外科 内科学
作者
Jiao Jiao,J Fan,Yonggang Zhang,Lingmin Chen
出处
期刊:Journal of Pain and Symptom Management [Elsevier BV]
卷期号:67 (3): e185-e210 被引量:6
标识
DOI:10.1016/j.jpainsymman.2023.11.004
摘要

Context Ketamine is a well-characterised anaesthetic agent, and subanesthetic ketamine possesses analgesic effects in both acute and chronic pain. Objectives A systematic review was performed to ascertain the efficacy and safety of ketamine in treating pain for cancer patients. Methods Eight databases were searched from the inception to March 20th, 2023 to obtain randomised controlled trials (RCTs) on ketamine for treating pain in cancer patients. Two reviewers independently screened studies, extracted the data and assessed the risk of bias of included studies; then, meta-analysis was performed by using Revman 5.3 software and Stata 14.0 software. Results 35 studies were included, involving 2279 patients with cancer pain. The results of meta-analysis showed that ketamine could significantly reduce pain intensity. Subgroup analysis revealed that, when compared with control group, ketamine decreased markedly visual analogue scale (VAS) scores in 2 days after the end of treatment with ketamine, and ketamine administrated by patient controlled epidural analgesia (PCEA) was effective. Meanwhile, ketamine could significantly reduce the number of patient-controlled analgesia (PCA) compressions within 24 hours and morphine dosage. Ketamine could not decrease Ramsay sedation score. Additionally, the adverse events significantly decreased in the ketamine group, including nausea and vomiting, constipation, pruritus, lethargy, uroschesis, hallucination, and respiratory depression. In addition, compared with the control group, ketamine could reduce Hamilton depression scale (HAMD) score and relieve depressive symptoms. Conclusion Ketamine may be used as an effective therapy to relieve cancer pain. However, more rigorously designed RCTs with larger sample sizes are required to verify the above conclusions.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
Li发布了新的文献求助10
刚刚
量子星尘发布了新的文献求助10
1秒前
研友_8y2G0L发布了新的文献求助10
1秒前
大意的天亦完成签到,获得积分20
2秒前
朝花夕拾完成签到,获得积分10
3秒前
FanFan完成签到,获得积分10
3秒前
打打应助科研通管家采纳,获得10
4秒前
充电宝应助科研通管家采纳,获得10
5秒前
乐观小之应助科研通管家采纳,获得10
5秒前
科目三应助科研通管家采纳,获得10
5秒前
乐观小之应助科研通管家采纳,获得10
5秒前
乐观小之应助科研通管家采纳,获得10
5秒前
yznfly应助科研通管家采纳,获得50
5秒前
乐观小之应助科研通管家采纳,获得10
5秒前
5秒前
5秒前
乐观小之应助科研通管家采纳,获得10
5秒前
5秒前
SYLH应助liaomr采纳,获得10
5秒前
6秒前
乔哥儿完成签到,获得积分10
6秒前
NexusExplorer应助跑在颖采纳,获得10
7秒前
7秒前
czwu完成签到,获得积分10
8秒前
cora驳回了Kin_L应助
8秒前
li2000722完成签到 ,获得积分10
9秒前
9秒前
扶溪筠完成签到,获得积分10
10秒前
wanci应助微笑傥采纳,获得10
11秒前
11秒前
郑凯歌发布了新的文献求助10
12秒前
青青子衿发布了新的文献求助10
12秒前
852应助认真盼曼采纳,获得10
13秒前
14秒前
15秒前
MHX完成签到,获得积分10
16秒前
曲沛萍发布了新的文献求助30
16秒前
花影完成签到 ,获得积分10
16秒前
17秒前
17秒前
高分求助中
A new approach to the extrapolation of accelerated life test data 1000
Cognitive Neuroscience: The Biology of the Mind 1000
Technical Brochure TB 814: LPIT applications in HV gas insulated switchgear 1000
ACSM’s Guidelines for Exercise Testing and Prescription, 12th edition 500
Picture Books with Same-sex Parented Families: Unintentional Censorship 500
Nucleophilic substitution in azasydnone-modified dinitroanisoles 500
不知道标题是什么 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 冶金 细胞生物学 免疫学
热门帖子
关注 科研通微信公众号,转发送积分 3969884
求助须知:如何正确求助?哪些是违规求助? 3514604
关于积分的说明 11174901
捐赠科研通 3249928
什么是DOI,文献DOI怎么找? 1795149
邀请新用户注册赠送积分活动 875599
科研通“疑难数据库(出版商)”最低求助积分说明 804891